{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:04:13Z","timestamp":1789506253448,"version":"build-2803163510"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004054","name":"King Abdulaziz University","doi-asserted-by":"publisher","award":["IPP: 1621-142-2025"],"award-info":[{"award-number":["IPP: 1621-142-2025"]}],"id":[{"id":"10.13039\/501100004054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Antibodies represent indispensable tools in the armamentarium against infectious diseases, with widespread application in prophylactic, therapeutic, and diagnostic settings. Conventional mammalian immunoglobulin G (IgG) antibodies have been extensively utilized in clinical and research contexts; however, their utility is sometimes constrained by intrinsic limitations such as thermal instability, susceptibility to proteolytic degradation, limited mucosal efficacy, and the high costs associated with mammalian expression systems. These challenges have driven increasing interest in alternative antibody formats derived from non-mammalian species that offer distinct structural and functional advantages. In recent years, a growing body of research has focused on non-canonical immunoglobulins, including immunoglobulin Y (IgY) from birds, nanobodies derived from the variable domain of heavy-chain-only antibodies (VHH) in camelids, and variable new antigen receptors (VNARs) sourced from the immunoglobulin new antigen receptor (IgNAR) system in cartilaginous fish such as sharks. The structural simplicity and functional robustness of these antibody platforms enable their integration into diverse biomedical applications, encompassing passive immunization, targeted drug delivery, and point-of-care diagnostics. Indeed, these molecules exhibit unique biochemical properties, including superior thermal and protease resistance, small molecular size, and the ability to access recessed or conformational epitopes that are often inaccessible to conventional IgG antibodies. Moreover, their typically lower immunogenic profiles and reduced pro-inflammatory activity render them suitable for a broad range of therapeutic strategies, including repeated administration and mucosal delivery, and position them as particularly promising agents for combating respiratory pathogens. This review highlights the unique properties, practical advantages, and translational therapeutic potential of IgY, nanobodies, and VNARs. It underscores their advantages over traditional antibody formats and their emerging role as next-generation Immunotherapeutics in the global effort to address persistent and emerging respiratory viral threats.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1723343","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:28:50Z","timestamp":1763706530000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Unique antibodies across the animal kingdom (birds, camelids, and sharks): therapeutic potential against human respiratory viral infections"],"prefix":"10.3389","volume":"16","author":[{"given":"Ammar A.","family":"Basabrain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thamir A.","family":"Alandijany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s43556-024-00210-1","article-title":"Monoclonal antibodies: From magic bullet to precision weapon","volume":"5","author":"Aboul-Ella","year":"2024","journal-title":"Mol Biomed"},{"key":"B2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduction Targeted Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1162342","article-title":"Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy","volume":"14","author":"Esposito","year":"2023","journal-title":"Front Immunol"},{"key":"B4","first-page":"14","article-title":"A brief synopsis of monoclonal antibody for the treatment of various groups of diseases","volume":"10","author":"Puthenpurail","year":"2021","journal-title":"World J Pharm Pharm Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1514224","article-title":"IgY antibodies for the immunoprophylaxis and therapy of respiratory infections","volume":"15","author":"Abbas","year":"2019","journal-title":"Hum Vaccines Immunotherapeut"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/biology14050547","article-title":"Nanobodies: from discovery to AI-driven design","volume":"14","author":"Zhu","year":"2025","journal-title":"Biology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1257042","article-title":"Unleashing the power of shark variable single domains (VNARs): broadly neutralizing tools for combating SARS-CoV-2","volume":"14","author":"Cabanillas-Bernal","year":"2023","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1389548","article-title":"Next generation single-domain antibodies against respiratory zoonotic RNA viruses","volume":"11","author":"Swart","year":"2024","journal-title":"Front Mol Biosci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1017\/S1466252315000195","article-title":"Passive immunization with hyperimmune egg-yolk IgY as prophylaxis and therapy for poultry diseases\u2013A review","volume":"16","author":"Gadde","year":"2015","journal-title":"Anim Health Res Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40364-021-00332-6","article-title":"A comprehensive comparison between camelid nanobodies and single chain variable fragments","volume":"9","author":"Asaadi","year":"2021","journal-title":"biomark Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"108808","DOI":"10.1016\/j.fsi.2023.108808","article-title":"Shark VNAR phage display libraries: An alternative source for therapeutic and diagnostic recombinant antibody fragments","volume":"138","author":"Manoutcharian","year":"2023","journal-title":"Fish Shellfish Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jim.2017.05.001","article-title":"Insights into the chicken IgY with emphasis on the generation and applications of chicken recombinant monoclonal antibodies","volume":"447","author":"Lee","year":"2017","journal-title":"J Immunol Methods"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(95)80008-5","article-title":"IgY: clues to the origins of modern antibodies","volume":"16","author":"Warr","year":"1995","journal-title":"Immunol Today"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830040715","article-title":"Immunoglobulin classes in the hen's egg: their segregation in yolk and white","volume":"4","author":"Rose","year":"1974","journal-title":"Eur J Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/brv.12325","article-title":"IgY: a key isotype in antibody evolution","volume":"92","author":"Zhang","year":"2017","journal-title":"Biol Rev Cambridge Philos Soc"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1271\/bbb.56.270","article-title":"Molecular stability of chicken and rabbit immunoglobulin G","volume":"56","author":"Shimizu","year":"1992","journal-title":"Biosci Biotechnol Biochem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-food-022811-101137","article-title":"Egg yolk antibodies for passive immunity","volume":"3","author":"Kovacs-Nolan","year":"2012","journal-title":"Annu Rev Food Sci Technol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3109\/10799893.2012.703207","article-title":"Progress on research of chicken IgY antibody-FcRY receptor combination and transfer","volume":"32","author":"Tian","year":"2012","journal-title":"J Receptor Signal Transduction Res"},{"key":"B19","first-page":"99","article-title":"Effect of chicken antibodies on inflammation in human lung epithelial cell lines","author":"Kubickova","year":"2014","journal-title":"Neuro Endocrinol Lett"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4161\/hv.23383","article-title":"Oral passive IgY-based immunotherapeutics: a novel solution for prevention and treatment of alimentary tract diseases","volume":"9","author":"Rahman","year":"2013","journal-title":"Hum Vaccines Immunotherapeut"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2018.06.023","article-title":"Production and application of anti-nucleoprotein IgY antibodies for influenza A virus detection in swine","volume":"461","author":"da Silva","year":"2018","journal-title":"J Immunol Methods"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2019.06.118","article-title":"Chicken egg yolk antibody (IgY) as diagnostics and therapeutics in parasitic infections - A review","volume":"136","author":"Thirumalai","year":"2019","journal-title":"Int J Biol Macromol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5851\/kosfa.2017.37.1.1","article-title":"Chicken egg yolk antibodies (IgY) for prophylaxis and treatment of rotavirus diarrhea in human and animal neonates: A concise review","volume":"37","author":"Thu","year":"2017","journal-title":"Korean J Food Sci Anim Resources"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/00071668.2011.646951","article-title":"IgY stability in eggs stored at room temperature or at +4 \u00b0C","volume":"53","author":"Nilsson","year":"2012","journal-title":"Br Poul Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.4.8.1970792","article-title":"Efficient production of chicken egg yolk antibodies against a conserved mammalian protein","volume":"4","author":"Gassmann","year":"1990","journal-title":"FASEB J: Off Publ Fed Am Societies Exp Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3109\/03009739909178961","article-title":"Chicken antibodies: a clinical chemistry perspective","volume":"104","author":"Carlander","year":"1999","journal-title":"Upsala J Med Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1163\/156856200743931","article-title":"A comparative study between the adsorption of IgY and IgG on latex particles","volume":"11","author":"D\u00e1valos-Pantoja","year":"2000","journal-title":"J Biomater Sci Polymer Ed"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3382\/ps.2008-00323","article-title":"Monitoring of laying capacity, immunoglobulin Y concentration, and antibody titer development in chickens immunized with ricin and botulinum toxins over a two-year period","volume":"88","author":"Pauly","year":"2009","journal-title":"Poul Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010152","article-title":"Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice","volume":"5","author":"Nguyen","year":"2010","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.11.005","article-title":"Preparation and characterization of egg yolk immunoglobulin Y specific to influenza B virus","volume":"93","author":"Wen","year":"2012","journal-title":"Antiviral Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jviromet.2014.05.016","article-title":"Prophylaxis and therapy of pandemic H1N1 virus infection using egg yolk antibody","volume":"206","author":"Yang","year":"2014","journal-title":"J Virol Methods"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040634","article-title":"Anti-S1 MERS-COV igY specific antibodies decreases lung inflammation and viral antigen positive cells in the human transgenic mouse model","volume":"8","author":"Abbas","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.3390\/ph14060511","article-title":"Immunotherapeutic efficacy of igY antibodies targeting the full-length spike protein in an animal model of middle east respiratory syndrome coronavirus infection","volume":"14","author":"El-Kafrawy","year":"2021","journal-title":"Pharmaceuticals"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/jam.15340","article-title":"Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker","volume":"132","author":"Bao","year":"2022","journal-title":"J Appl Microbiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.881604","article-title":"Preclinical assessment of igY antibodies against recombinant SARS-coV-2 RBD protein for prophylaxis and post-infection treatment of COVID-19","volume":"13","author":"Agurto-Arteaga","year":"2022","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010782","article-title":"SARS-CoV-2-specific immunoglobulin Y antibodies are protective in infected mice","volume":"18","author":"El-Kafrawy","year":"2022","journal-title":"PloS Pathogens"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.899617","article-title":"Egg-derived anti-SARS-coV-2 immunoglobulin Y (IgY) with broad variant activity as intranasal prophylaxis against COVID-19","volume":"13","author":"Frumkin","year":"2022","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3390\/vaccines12121422","article-title":"Evaluating the protective role of intranasally administered avian-derived igY against SARS-coV-2 in Syrian hamster models","volume":"12","author":"Madai","year":"2024","journal-title":"Vaccines"},{"key":"B39","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40659-024-00508-y","article-title":"Rapid development and mass production of SARS-CoV-2 neutralizing chicken egg yolk antibodies with protective efficacy in hamsters","volume":"57","author":"Zhao","year":"2024","journal-title":"Biol Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2011.410","article-title":"Antibodies against swine influenza virus neutralize the pandemic influenza virus A\/H1N1","volume":"4","author":"Tsukamoto","year":"2011","journal-title":"Mol Med Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05075-11","article-title":"Cross-protection of chicken immunoglobulin Y antibodies against H5N1 and H1N1 viruses passively administered in mice","volume":"18","author":"Wallach","year":"2011","journal-title":"Clin Vaccine Immunol: CVI"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2005.10.027","article-title":"Preparation and evaluation of anti-SARS coronavirus IgY from yolks of immunized SPF chickens","volume":"133","author":"Fu","year":"2006","journal-title":"J Virol Methods"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1596514","article-title":"Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform","volume":"11","author":"Gjetting","year":"2019","journal-title":"mAbs"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991931","article-title":"Trends in industrialization and commercialization of IgY technology","volume":"13","author":"Yakhkeshi","year":"2022","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.provac.2012.04.006","article-title":"Chicken egg yolk antibodies against bovine respiratory syncytial virus neutralize the virus in vitro","volume":"6","author":"Ferella","year":"2012","journal-title":"Proc Vaccinol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2020.8704","article-title":"IgY - turning the page toward passive immunization in COVID-19 infection (Review)","volume":"20","author":"Constantin","year":"2020","journal-title":"Exp Ther Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.2c09180","article-title":"Egg yolk antibody for passive immunization: status, challenges, and prospects","volume":"71","author":"Wang","year":"2023","journal-title":"J Agric Food Chem"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2174\/0115680266289898240322073258","article-title":"Use of immunoglobulin Y antibodies: biosensor-based diagnostic systems and prophylactic and therapeutic drug delivery systems for viral respiratory diseases","volume":"24","author":"Budama-Kilinc","year":"2024","journal-title":"Curr Topics Med Chem"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/363446a0","article-title":"Naturally occurring antibodies devoid of light chains","volume":"363","author":"Hamers-Casterman","year":"1993","journal-title":"Nature"},{"key":"B50","doi-asserted-by":"publisher","first-page":"7934","DOI":"10.1038\/s41598-018-26338-z","article-title":"The structural basis of nanobody unfolding reversibility and thermoresistance","volume":"8","author":"Kunz","year":"2018","journal-title":"Sci Rep"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(97)00146-6","article-title":"Comparison of llama VH sequences from conventional and heavy chain antibodies","volume":"34","author":"Vu","year":"1997","journal-title":"Mol Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/374168a0","article-title":"A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks","volume":"374","author":"Greenberg","year":"1995","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.435289","article-title":"Atypical antigen recognition mode of a shark immunoglobulin new antigen receptor (IgNAR) variable domain characterized by humanization and structural analysis","volume":"288","author":"Kovalenko","year":"2013","journal-title":"J Biol Chem"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1303353","article-title":"Nanobodies: a promising approach to treatment of viral diseases","volume":"14","author":"Minatel","year":"2024","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"100054","DOI":"10.1016\/j.bea.2022.100054","article-title":"Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses","volume":"4","author":"Lim","year":"2022","journal-title":"Biomed Eng Adv"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.13.3512","article-title":"Potent enzyme inhibitors derived from dromedary heavy-chain antibodies","volume":"17","author":"Lauwereys","year":"1998","journal-title":"EMBO J"},{"key":"B57","doi-asserted-by":"publisher","first-page":"7850","DOI":"10.1038\/srep07850","article-title":"Selection of nanobodies that block the enzymatic and cytotoxic activities of the binary Clostridium difficile toxin CDT","volume":"5","author":"Unger","year":"2015","journal-title":"Sci Rep"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.cell.2022.03.009","article-title":"Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody","volume":"185","author":"Li","year":"2022","journal-title":"Cell"},{"key":"B59","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1389-0352(01)00021-6","article-title":"Single domain camel antibodies: current status","volume":"74","author":"Muyldermans","year":"2001","journal-title":"J Biotechnol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00063030-200923020-00003","article-title":"Strategies to extend plasma half-lives of recombinant antibodies","volume":"23","author":"Kontermann","year":"2009","journal-title":"BioDrugs: Clin Immunotherapeut Biopharmaceut Gene Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/biom10121661","article-title":"Picomolar SARS-coV-2 neutralization using multi-arm PEG nanobody constructs","volume":"10","author":"Moliner-Morro","year":"2020","journal-title":"Biomolecules"},{"key":"B62","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41467-021-27610-z","article-title":"A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo","volume":"13","author":"Hanke","year":"2022","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1126\/science.aaq0620","article-title":"Universal protection against influenza infection by a multidomain antibody to influenza hemagglutinin","volume":"362","author":"Laursen","year":"2018","journal-title":"Sci (New York NY)"},{"key":"B64","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41467-024-55193-y","article-title":"Influenza A Virus H7 nanobody recognizes a conserved immunodominant epitope on hemagglutinin head and confers heterosubtypic protection","volume":"16","author":"Chen","year":"2025","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/v14112485","article-title":"Cross-reactive fc-fused single-domain antibodies to hemagglutinin stem region protect mice from group 1 influenza a virus infection","volume":"14","author":"Voronina","year":"2022","journal-title":"Viruses"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03178-13","article-title":"Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge","volume":"88","author":"Cardoso","year":"2014","journal-title":"J Virol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028309","article-title":"Potent neutralization of influenza A virus by a single-domain antibody blocking M2 ion channel protein","volume":"6","author":"Wei","year":"2011","journal-title":"PloS One"},{"key":"B68","doi-asserted-by":"publisher","first-page":"4420","DOI":"10.1038\/s41467-020-18174-5","article-title":"An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction","volume":"11","author":"Hanke","year":"2020","journal-title":"Nat Commun"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe3255","article-title":"An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike","volume":"370","author":"Schoof","year":"2020","journal-title":"Sci (New York NY)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abi7826","article-title":"An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models","volume":"13","author":"Schepens","year":"2021","journal-title":"Sci Trans Med"},{"key":"B71","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41392-024-01940-y","article-title":"Enhancing RBD exposure and S1 shedding by an extremely conserved SARS-CoV-2 NTD epitope","volume":"9","author":"Zhu","year":"2024","journal-title":"Signal Transduction Targeted Ther"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe6230","article-title":"Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape","volume":"371","author":"Koenig","year":"2021","journal-title":"Sci (New York NY)"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2047144","DOI":"10.1080\/19420862.2022.2047144","article-title":"Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19","volume":"14","author":"Esparza","year":"2022","journal-title":"mAbs"},{"key":"B74","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1038\/s41467-021-25480-z","article-title":"A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19","volume":"12","author":"Huo","year":"2021","journal-title":"Nat Commun"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.865401","article-title":"Short-term instantaneous prophylaxis and efficient treatment against SARS-coV-2 in hACE2 mice conferred by an intranasal nanobody (Nb22)","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"105778","DOI":"10.1016\/j.antiviral.2023.105778","article-title":"Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters","volume":"221","author":"Aksu","year":"2024","journal-title":"Antiviral Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aas9667","article-title":"Chimeric camel\/human heavy-chain antibodies protect against MERS-CoV infection","volume":"4","author":"Stalin Raj","year":"2018","journal-title":"Sci Adv"},{"key":"B78","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S2213-2600(20)30320-9","article-title":"Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Cunningham","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir622","article-title":"Nanobodies\u00ae Specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion","volume":"204","author":"Schepens","year":"2011","journal-title":"J Infect Dis"},{"key":"B80","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1128\/AAC.01802-15","article-title":"Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection","volume":"60","author":"Detalle","year":"2015","journal-title":"Antimicrobial Agents Chemother"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2018.1470727","article-title":"Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs","volume":"10","author":"Larios Mora","year":"2018","journal-title":"mAbs"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.02122-23","article-title":"A neutralizing single-domain antibody that targets the trimer interface of the human metapneumovirus fusion protein","volume":"15","author":"Ballegeer","year":"2024","journal-title":"mBio"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.chom.2023.07.002","article-title":"Potent cross-neutralization of respiratory syncytial virus and human metapneumovirus through a structurally conserved antibody recognition mode","volume":"31","author":"Wen","year":"2023","journal-title":"Cell Host Microbe"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq168","article-title":"Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection","volume":"203","author":"Iba\u00f1ez","year":"2011","journal-title":"J Infect Dis"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0301664","article-title":"Anti-hemagglutinin monomeric nanobody provides prophylactic immunity against H1 subtype influenza A viruses","volume":"19","author":"Barbieri","year":"2024","journal-title":"PloS One"},{"key":"B86","doi-asserted-by":"publisher","first-page":"116781","DOI":"10.1016\/j.biopha.2024.116781","article-title":"H1N1 nanobody development and therapeutic efficacy verification in H1N1-challenged mice","volume":"176","author":"Hwang","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00837-18","article-title":"A novel nanobody targeting middle east respiratory syndrome coronavirus (MERS-coV) receptor-binding domain has potent cross-neutralizing activity and protective efficacy against MERS-coV","volume":"92","author":"Zhao","year":"2018","journal-title":"J Virol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/j.cell.2020.05.047","article-title":"Structural basis for potent neutralization of betacoronaviruses by single-domain camelid antibodies","volume":"181","author":"Wrapp","year":"2020","journal-title":"Cell"},{"key":"B89","doi-asserted-by":"publisher","first-page":"109869","DOI":"10.1016\/j.celrep.2021.109869","article-title":"A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration","volume":"37","author":"Wu","year":"2021","journal-title":"Cell Rep"},{"key":"B90","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41419-024-06802-7","article-title":"A broad neutralizing nanobody against SARS-CoV-2 engineered from an approved drug","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis"},{"key":"B91","doi-asserted-by":"publisher","first-page":"105736","DOI":"10.1016\/j.isci.2022.105736","article-title":"Screening and characterization of inhibitory vNAR targeting nanodisc-assembled influenza M2 proteins","volume":"26","author":"Yu","year":"2023","journal-title":"iScience"},{"key":"B92","doi-asserted-by":"publisher","first-page":"7325","DOI":"10.1038\/s41467-021-27611-y","article-title":"Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography","volume":"12","author":"Ubah","year":"2021","journal-title":"Nat Commun"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202200387","article-title":"A class of shark-derived single-domain antibodies can broadly neutralize SARS-related coronaviruses and the structural basis of neutralization and omicron escape","volume":"6","author":"Feng","year":"2022","journal-title":"Small Methods"},{"key":"B94","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41467-023-36106-x","article-title":"Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity","volume":"14","author":"Chen","year":"2023","journal-title":"Nat Commun"},{"key":"B95","doi-asserted-by":"publisher","first-page":"105898","DOI":"10.1016\/j.antiviral.2024.105898","article-title":"Screening and optimization of shark nanobodies against SARS-CoV-2 spike RBD","volume":"226","author":"Liu","year":"2024","journal-title":"Antiviral Res"},{"key":"B96","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12951-025-03150-2","article-title":"A shark-derived broadly neutralizing nanobody targeting a highly conserved epitope on the S2 domain of sarbecoviruses","volume":"23","author":"Feng","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antib8010001","article-title":"Single-domain antibodies and their formatting to combat viral infections","volume":"8","author":"De Vlieger","year":"2018","journal-title":"Antibodies (Basel Switzerland)"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3390\/v14061162","article-title":"Single-domain antibodies as therapeutics for respiratory RNA virus infections","volume":"14","author":"Huang","year":"2022","journal-title":"Viruses"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1723343\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:28:53Z","timestamp":1763706533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1723343\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":98,"alternative-id":["10.3389\/fimmu.2025.1723343"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1723343","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"article-number":"1723343"}}